论文部分内容阅读
在400名接受胺碘达隆治疗的病人中,对97人进行了甲状腺机能测定;其中证实甲状腺毒性症状者有20人,而甲状腺机能减退者有16人。在甲状腺毒性症状的病人中,用胺碘哒隆治疗后2～36个月出现症状;最特异的是实验室发现总T_3(TT_3)增高。抗甲状腺治疗无效,而在停用胺碘哒隆后3～7个月甲状腺功能恢复正常。在甲状腺机能减退的一组中,最特异性的实验室发现是TSH增高,这些病人在停服或继续服胺碘哒隆的同时给予替代疗法。在部分用胺碘哒隆的病人中甲状腺的碘含量通过X线荧光法予以测定。凡发展成甲状腺毒性症状的病人中显示了特别高的含碘量。在用胺碘达隆治疗期间,病人是否会发展成甲状腺毒性症状可从TT_3值增高以及高的甲状腺含碘量予以辨认。在这些特殊病人当中,应减少其维持量。
Of the 400 patients treated with amiodarone, 97 had thyroid function tests, of whom 20 had confirmed thyrotoxicosis and 16 had hypothyroidism. In patients with thyrotoxicosis, symptoms appear 2 to 36 months after treatment with amiodarone; the most specific is the increase in total T_3 (TT_3) found in the laboratory. Anti-thyroid treatment is ineffective, and in the deactivation of amiodarone after 3 to 7 months of thyroid function returned to normal. In the group of hypothyroidism, the most specific laboratory finding was an increase in TSH, and these patients were given alternative therapy with or without amiodarone. The iodine content of the thyroid in some patients treated with pyridalindine was determined by X-ray fluorescence. Patients who developed symptoms of thyrotoxicosis showed particularly high levels of iodine. During treatment with amiodarone, whether a patient develops thyrotoxicosis can be identified by increased TT_3 and high thyroid iodine levels. Among these special patients, their maintenance should be reduced.